Knight Therapeutics Inc. (FRA:04K)

Market Cap	457.35M +25.6%
Revenue (ttm)	279.58M +21.2%
Net Income	-3.34M
EPS	-0.03
Shares Out	n/a
PE Ratio	n/a
Forward PE	52.35
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	4.640
Previous Close	4.600
Day's Range	4.640 - 4.640
52-Week Range	3.460 - 4.780
Beta	n/a
RSI	59.42
Earnings Date	May 7, 2026

About Knight Therapeutics

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ...

• Industry: Pharmaceutical Preparations
• Founded: 2013
• Employees: 830
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 04K

Financial Performance

Financial numbers in CAD